Injection of nanoparticle has proven effective in mouse models, researchers say
Researchers at Tel Aviv University have developed a novel nano-vaccine for melanoma, the most aggressive type of skin cancer. Their innovative approach has so far proven effective in preventing the development of melanoma in mouse models and in treating primary tumors and metastases that result from melanoma.
The focus of the research is on a nanoparticle that serves as the basis for the new vaccine. The study was led by Prof. Ronit Satchi-Fainaro, chair of the Department of Physiology and Pharmacology and head of the Laboratory for Cancer Research and Nanomedicine at TAU’s Sackler Faculty of Medicine, and Prof. Helena Florindo of the University of Lisbon while on sabbatical at the Satchi-Fainaro lab at TAU; it was conducted by Dr. Anna Scomparin of Prof. Satchi-Fainaro’s TAU lab and postdoctoral fellow Dr. João Conniot. The results were published on August 5 in Nature Nanotechnology.
Melanoma develops in the skin cells that produce melanin or skin pigment. “The war against cancer in general, and melanoma in particular, has advanced over the years through a variety of treatment modalities, such as chemotherapy, radiation therapy and immunotherapy; but the vaccine approach, which has proven so effective against various viral diseases, has not materialized yet against cancer,” says Prof. Satchi-Fainaro. “In our study, we have shown for the first time that it is possible to produce an effective nano-vaccine against melanoma and to sensitize the immune system to immunotherapies.”
The researchers harnessed tiny particles, about 170 nanometers in size, made of a biodegradable polymer. Within each particle, they “packed” two peptides — short chains of amino acids, which are expressed in melanoma cells. They then injected the nanoparticles (or “nano-vaccines”) into a mouse model bearing melanoma.
“The nanoparticles acted just like known vaccines for viral-borne diseases,” Prof. Satchi-Fainaro explains. “They stimulated the immune system of the mice, and the immune cells learned to identify and attack cells containing the two peptides — that is, the melanoma cells. This meant that, from now on, the immune system of the immunized mice will attack melanoma cells if and when they appear in the body.”
The researchers then examined the effectiveness of the vaccine under three different conditions.
First, the vaccine proved to have prophylactic effects. The vaccine was injected into healthy mice, and an injection of melanoma cells followed. “The result was that the mice did not get sick, meaning that the vaccine prevented the disease,” says Prof. Satchi-Fainaro.
Second, the nanoparticle was used to treat a primary tumor: A combination of the innovative vaccine and immunotherapy treatments was tested on melanoma model mice. The synergistic treatment significantly delayed the progression of the disease and greatly extended the lives of all treated mice.
Finally, the researchers validated their approach on tissues taken from patients with melanoma brain metastases. This suggested that the nano-vaccine can be used to treat brain metastases as well. Mouse models with late-stage melanoma brain metastases had already been established following excision of the primary melanoma lesion, mimicking the clinical setting. Research on image-guided surgery of primary melanoma using smart probes was published last year by Prof. Satchi-Fainaro’s lab.
“Our research opens the door to a completely new approach — the vaccine approach — for effective treatment of melanoma, even in the most advanced stages of the disease,” concludes Prof. Satchi-Fainaro. “We believe that our platform may also be suitable for other types of cancer and that our work is a solid foundation for the development of other cancer nano-vaccines.”
The Latest on: Melanoma
via Google News
The Latest on: Melanoma
- Iovance Stock Down on Delay in Filing for Melanoma Candidateon October 7, 2020 at 8:32 am
Shares of Iovance Biotherapeutics, Inc. IOVA fell about 12.4% after it announced that it will delay its biologics license application (BLA) submission to the FDA for its tumor-infiltrating lymphocyte ...
- Risk of melanoma may be gauged long before suspicious moles appear – studyon October 7, 2020 at 6:02 am
Research suggests genomic methods used to probe skin damage could be developed to estimate baseline risk of the skin cancer.
- Iovance stock drops nearly 10% following snag with FDA over experimental melanoma treatmenton October 6, 2020 at 11:22 am
Shares of Iovance Biotherapeutics, which is building a commercial manufacturing and office complex at the Philadelphia Navy Yard, were down 10% Tuesday on news about its experimental melanoma ...
- Iovance's stock tumbles over questions about regulatory submission for melanoma drugon October 6, 2020 at 5:08 am
Shares of Iovance Biotherapeutics Inc. were down 20.0% in premarket trading on Tuesday, the day after the biotechnology company said it plans to now submit an application to the Food and Drug ...
- Iovance Biotherapeutics Provides Update for Lifileucel in Metastatic Melanomaon October 5, 2020 at 1:01 pm
(GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today provided a regulatory update for its ...
- Bristol Myers Opdivo + Yervoy again shows underwhelming response in melanoma studyon October 5, 2020 at 4:50 am
Bristol (NYSE:BMY) announces results for the co-primary endpoint for CheckMate-915, a randomized Phase 3 study evaluating Opdivo (nivolumab) plus Yervoy (ipilimumab) versus Opdivo for patients ...
- Ultimovacs Announces Positive Topline Results from Phase I Combination Trial Evaluating Universal Cancer Vaccine, UV1, in Malignant Melanoma Patientson September 30, 2020 at 8:27 am
Ultimovacs ASA ("Ultimovacs", ticker ULTIMO), today announced positive topline results from the first cohort of 20 patients in its ongoing US-based Phase I clinical trial evaluating the Company’s lead ...
- Melanoma Detection Market 2020 : Top Countries Data with Market Size, Share, Growth Analysis, Industry basis of Region to 2026on September 30, 2020 at 2:18 am
Melanoma Detection Market"Research Report 2020-2026 provides key analysis on the market status of the Melanoma ...
- Surgeon general’s disclosure puts spotlight on melanomaon September 29, 2020 at 9:16 am
According to the U.S. Centers for Disease Control and Prevention, the incidences of melanoma has doubled during the past three decades and just recently U.S. Surgeon General Jerome Adams acknowledged ...
- Melanoma Drugs Market 2020 is Evolving Rapidly with Economic Growth, Demand Analysis, Geographical Segmentation and Forthcoming Opportunitieson September 28, 2020 at 8:46 pm
The Global Melanoma Drugs Market 2020 Global Industry Size, Share, Forecasts Analysis, Company Profiles, Competitive Landscape and Key Regions 2026 Analysis, Latest Innovations, Impacting Factors, ...
via Bing News